Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
557.00    0.00 (0.00%)
Bid:
556.00
Ask:
557.00
Spread: 1.00 (0.18%)
Market Cap: £2.47b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Directorate Change

24 Apr 2024 07:00

RNS Number : 7510L
Tate & Lyle PLC
24 April 2024
 

 

Tate & Lyle PLC - 24 April 2024

 

DIRECTORATE CHANGE

 

Tate & Lyle PLC (Tate & Lyle) announces that Dawn Allen, Chief Financial Officer, has decided to leave the Company to take up the position of Chief Financial Officer of Haleon plc. Mrs Allen will remain with Tate & Lyle until October 2024 to close out our half-year results ending 30 September 2024, and to support an orderly transition.

 

The Board has begun a process to appoint a successor to Mrs Allen and a further announcement will be made in due course.

 

Nick Hampton, Chief Executive said: "During her time at Tate & Lyle, Dawn has played a key role in maintaining strong financial discipline across the business, and leaves behind a proven team that will continue to support the delivery of our growth-focused strategy. We wish her every success in the next stage of her career."

 

David Hearn, Chair, said: "Dawn has been a valued member of the management team and on behalf of the Board I would like to thank her for her contribution to Tate & Lyle, and wish her all the best in her next role."

 

 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Nick Hasell, FTI Consulting (Media)

Tel: +44 (0) 203 727 1340

 

 

About Tate & Lyle:

Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

 

Through our expertise in sweetening, fortification, and texture, we develop ingredient solutions which reduce sugar, calories, and fat, add fibre and protein, and provide texture and stability in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

 

We have more than 3,500 employees working in around 57 locations across 39 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives Through the Science of Food. By living our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2023, Tate & Lyle revenue from continuing operations totalled £1.75 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on Linkedin, X (Twitter), Facebook or YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASELFIDELSEIL
Date   Source Headline
15th May 202610:24 amBUSDimensional Fund Advisors Ltd. : Form 8.3 - TATE & LYLE PLC - Ordinary Shares
15th May 20268:56 amRNSForm 8.5 (EPT/RI)
14th May 20264:15 pmRNSPossible 595 pence all-cash offer for Tate & Lyle
14th May 20263:25 pmRNSForm 8.3 - Tate & Lyle plc
14th May 20261:24 pmRNSDisclosure Table
14th May 20261:07 pmRNSStatement re Possible Offer for Tate & Lyle
1st May 202610:00 amRNSTotal Voting Rights
1st Apr 20264:00 pmRNSHolding(s) in Company
27th Mar 20262:00 pmRNSHolding(s) in Company
13th Mar 20264:00 pmRNSHolding(s) in Company
2nd Mar 20262:00 pmRNSHolding(s) in Company
26th Feb 20267:00 amRNSTrading Statement
23rd Feb 202610:00 amRNSHolding(s) in Company
17th Feb 202612:00 pmRNSHolding(s) in Company
21st Jan 20267:00 amRNSDirectorate change
15th Jan 20269:00 amRNSHolding(s) in Company
12th Jan 202610:00 amRNSHolding(s) in Company
7th Jan 20264:30 pmRNSDirector/PDMR Shareholding
7th Jan 20262:30 pmRNSBlock listing Interim Review
18th Dec 20252:00 pmRNSDirector/PDMR Shareholding
18th Dec 20252:00 pmRNSDirector/PDMR Shareholding
11th Dec 202512:18 pmRNSDirector/PDMR Shareholding
9th Dec 20259:00 amRNSHolding(s) in Company
27th Nov 202510:00 amRNSDirector/PDMR Shareholding
11th Nov 20254:30 pmRNSDirector/PDMR Shareholding
10th Nov 20252:40 pmRNSDirector Declaration
6th Nov 20257:00 amRNSHalf-year Financial Report
5th Nov 20252:15 pmRNSHolding(s) in Company
3rd Nov 20255:00 pmRNSHolding(s) in Company
29th Oct 20252:00 pmRNSHolding(s) in Company
23rd Oct 20254:15 pmRNSHolding(s) in Company
21st Oct 20253:30 pmRNSHolding(s) in Company
16th Oct 202512:00 pmRNSHolding(s) in Company
8th Oct 202512:00 pmRNSHolding(s) in Company
6th Oct 20254:30 pmRNSDirector/PDMR Shareholding
6th Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 202510:00 amRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSPre-close statement
2nd Sep 20258:00 amRNSTotal Voting Rights
11th Aug 20251:00 pmRNSDirector/PDMR Shareholding
5th Aug 20257:00 amRNSDirector/PDMR Shareholding
1st Aug 202511:00 amRNSTotal Voting Rights
24th Jul 20252:30 pmRNSResult of Annual General Meeting 2025
15th Jul 20251:00 pmRNSDirector/PDMR Shareholding
1st Jul 20253:30 pmRNSBlock listing Interim Review
1st Jul 20257:00 amRNSTate & Lyle Capital Markets Event
13th Jun 20253:00 pmRNSHolding(s) in Company
11th Jun 20254:30 pmRNSDirector/PDMR Shareholding
5th Jun 20252:30 pmRNSAnnual Financial Report and Notice of Meeting 2025

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.